GoKawiil
Tech News
Novo Nordisk, the Danish pharmaceutical company known for Ozempic and Wegovy, is rebranding itself as simply 'Novo' starting this week. The move shifts the company's public identity toward a shorter, more casual name as it markets directly to consumers rather than solely to healthcare providers.
The Guardian gathered reader accounts describing how GLP-1 drugs like Wegovy, Ozempic and Mounjaro have reshaped family dynamics, with many users hiding their use out of shame. Several described feeling they had 'cheated' at weight loss, straining relationships with partners, children and friends who didn't know about the medication.
A growing number of children and teenagers with obesity or type 2 diabetes are being prescribed GLP-1 medications, drugs originally developed for adults. Physicians and researchers say long-term safety and developmental effects of these treatments in younger patients remain largely unstudied.
Chinese pharmaceutical companies, once known mainly for producing cheap generic medicines, are now developing original obesity and weight-loss drugs aimed at competing with Western blockbusters like Ozempic and Wegovy. Several firms are advancing candidates through clinical trials and striking licensing deals with major international drugmakers.